{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T14:01:54Z","timestamp":1777816914830,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T00:00:00Z","timestamp":1494633600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12325-017-0549-0","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T06:52:56Z","timestamp":1494658376000},"page":"1411-1425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence"],"prefix":"10.1007","volume":"34","author":[{"given":"Yasuaki","family":"Kuwayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Kakegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,13]]},"reference":[{"key":"549_CR1","volume-title":"Terminology and guidelines for glaucoma","author":"European Glaucoma Society","year":"2008","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: DOGMA; 2008.","edition":"3"},{"key":"549_CR2","first-page":"1595","volume":"25","author":"Y Kuwayama","year":"2008","unstructured":"Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015% DE-085 (tafluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashii Ganka (J Eye). 2008;25:1595\u2013602.","journal-title":"Atarashii Ganka (J Eye)"},{"key":"549_CR3","first-page":"436","volume":"114","author":"Y Kuwayama","year":"2010","unstructured":"Kuwayama Y, Komemushi S, Tafluprost Multi-center Study Group. Intraocular pressure-lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal-tension glaucoma: randomized, double-blind, multicenter, phase III study. Nippon Ganka Gakkai Zasshi. 2010;114:436\u201343.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"549_CR4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12325-014-0109-9","volume":"31","author":"Y Kuwayama","year":"2014","unstructured":"Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31:461\u201371.","journal-title":"Adv Ther"},{"key":"549_CR5","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology"},{"key":"549_CR6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/jop.2015.0086","volume":"32","author":"K Inoue","year":"2016","unstructured":"Inoue K, Setogawa A, Tomita G. Nonresponders to prostaglandin analogs among normal-tension glaucoma patients. J Ocul Pharmacol Ther. 2016;32:90\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"key":"549_CR7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10384-012-0199-3","volume":"57","author":"T Yoshino","year":"2013","unstructured":"Yoshino T, Fukuchi T, Togano T, Seki M, Ikegaki H, Abe H. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases. Jpn J Ophthalmol. 2013;57:172\u20138.","journal-title":"Jpn J Ophthalmol"},{"key":"549_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/jop.2008.0072","volume":"25","author":"TJ Zimmerman","year":"2009","unstructured":"Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25:145\u201352.","journal-title":"J Ocul Pharmacol Ther"},{"key":"549_CR9","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1136\/bjo.2003.037713","volume":"88","author":"Z Zhou","year":"2004","unstructured":"Zhou Z, Althin R, Sforzolini BS, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol. 2004;88:1391\u20134.","journal-title":"Br J Ophthalmol"},{"key":"549_CR10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598\u2013606.","journal-title":"Am J Ophthalmol"},{"key":"549_CR11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/eye.2008.213","volume":"23","author":"CG Owen","year":"2009","unstructured":"Owen CG, Carey IM, de Wilde S, Whincup PH, Wormald R, Cook DG. Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994\u20132005. Eye. 2009;23:1098\u2013110.","journal-title":"Eye"},{"key":"549_CR12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/bjo.2010.188607","volume":"95","author":"MQ Rahman","year":"2011","unstructured":"Rahman MQ, Abeysinghe SS, Kelly S, et al. Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database. Br J Ophthalmol. 2011;95:966\u201370.","journal-title":"Br J Ophthalmol"},{"key":"549_CR13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1089\/jop.2011.0051","volume":"27","author":"G Holl\u00f3","year":"2011","unstructured":"Holl\u00f3 G, Thelen U, Teus MA, et al. Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe. J Ocul Pharmacol Ther. 2011;27:493\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"549_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1755-3768.2009.01663.x","volume":"88","author":"B Fristr\u00f6m","year":"2010","unstructured":"Fristr\u00f6m B, Uusitalo H. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Acta Ophthalmol. 2010;88:37\u201343.","journal-title":"Acta Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0549-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T07:36:15Z","timestamp":1497252975000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0549-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,13]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0549-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,13]]}}}